Researchers from Weill Cornell Medicine and Sweden’s Linköping University have discovered that the anesthetic propofol could lead to new treatments for epilepsy and other neurological disorders. Published on July 31 in Nature, the study reveals how propofol inhibits the ion channel protein HCN1, which is involved in neuron activity and linked to epilepsy.
The research team, led by Crina Nimigean and Peter Larsson, found that propofol can restore normal function in HCN1 channels with mutations that cause drug-resistant epilepsy. This discovery suggests the potential to repurpose propofol for treating epilepsy or develop new drugs with similar mechanisms but fewer side effects.
The study highlights the need for further research into how propofol selectively inhibits HCN1 over other channels, aiming to design more targeted therapies for HCN1-linked disorders.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].